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In the brain, metabolism of the essential branched chain amino acids (BCAAs) leucine,
isoleucine, and valine, is regulated in part by protein synthesis requirements. Excess
BCAAs are catabolized or excreted. The first step in BCAA catabolism is catalyzed by the
branched chain aminotransferase (BCAT) isozymes, mitochondrial BCATm and cytosolic
BCATc. A product of this reaction, glutamate, is the major excitatory neurotransmitter
and precursor of the major inhibitory neurotransmitter γ-aminobutyric acid (GABA).
The BCATs are thought to participate in a α-keto-acid nitrogen shuttle that provides
nitrogen for synthesis of glutamate from α-ketoglutarate. The branched-chain α-keto acid
dehydrogenase enzyme complex (BCKDC) catalyzes the second, irreversible step in BCAA
metabolism, which is oxidative decarboxylation of the branched-chain α-keto acid (BCKA)
products of the BCAT reaction. Maple Syrup Urine Disease (MSUD) results from genetic
defects in BCKDC, which leads to accumulation of toxic levels of BCAAs and BCKAs that
result in brain swelling. Immunolocalization of BCATm and BCKDC in rats revealed that
BCATm is present in astrocytes in white matter and in neuropil, while BCKDC is expressed
only in neurons. BCATm appears uniformly distributed in astrocyte cell bodies throughout
the brain. The segregation of BCATm to astrocytes and BCKDC to neurons provides
further support for the existence of a BCAA-dependent glial-neuronal nitrogen shuttle
since the data show that BCKAs produced by glial BCATm must be exported to neurons.
Additionally, the neuronal localization of BCKDC suggests that MSUD is a neuronal defect
involving insufficient oxidation of BCKAs, with secondary effects extending beyond the
neuron.
Keywords: glutamate, gamma-amino butyric acid, MSUD, branched chain aminotransferase, traumatic brain
injury, branched chain amino acid
INTRODUCTION
The three nutritionally essential branched chain amino acids
(BCAAs), leucine, isoleucine, and valine, contribute nitrogen to
the glutamate/glutamine cycle (Hutson et al., 2005; Yudkoff et al.,
2005). These amino acids provide approximately 30–50% of the
nitrogen for de novo glutamate synthesis in astrocytes (Kanamori
et al., 1998). In the central nervous system (CNS), glutamate
that is formed from BCAA transamination is an excitatory neu-
rotransmitter and substrate for synthesis of the major inhibitory
neurotransmitter γ-aminobutyric acid (GABA). Current theories
of the function of BCAAs in brain are consistent with involvement
of the glutamatergic and/or GABAergic systems in the etiology of
neurological disorders (Bixel andHamprecht, 1995; Yudkoff et al.,
1996a,b; Yudkoff, 1997; Hutson et al., 1998, 2001; Kanamori et al.,
1998; Sakai et al., 2004).
The first step in the catabolism of the BCAAs is reversible
transamination catalyzed by the branched chain aminotrans-
ferase (BCAT) isozymes. There are two known mammalian
BCAT isozymes-cytosolic (BCATc) and mitochondrial (BCATm)
(Ichihara, 1985). Both BCAT enzymes reversibly transfer the
α-amino group of a BCAA to an amino group acceptor, generally
α-ketoglutarate. The products of the BCAT reaction are glutamate
and the respective branched chain α-keto acids (BCKAs), which
are α-ketoisocaproate (KIC), α-keto-β-methylvalerate (KMV),
and α-ketoisovalerate (KIV). BCATc is the predominant BCAT
isozyme in the CNS (Ichihara, 1985; Hall et al., 1993; Sweatt et al.,
2004a,b). Previously, this laboratory has demonstrated BCATc
expression in select populations of glutamatergic and GABAergic
neurons (Sweatt et al., 2004b; Garcia-Espinosa et al., 2007). There
is evidence that BCATm does not co-localize with BCATc, rather
it is enriched in astrocytes (Bixel et al., 1997, 2001; Hutson et al.,
1998; LaNoue et al., 2001), however, the detailed distribution of
BCATm in the CNS has not yet been determined. It has been pro-
posed that the BCAT isozymes participate in a nitrogen cycle that
drives de novo synthesis of neurotransmitter glutamate in astro-
cytes (Hutson et al., 1998, 2001; LaNoue et al., 2001), facilitates
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nitrogen transfer for neurotransmitter glutamate in neurons and
acts as a buffer to maintain glutamate levels in neurons (Yudkoff
et al., 1993).
The second and irreversible step in BCAA catabolism is cat-
alyzed by the mitochondrial branched chain α-keto acid dehydro-
genase (BCKDC) enzyme complex (Harris et al., 1990). BCKDC
catalyzes oxidative decarboxylation of the BCKA products of the
BCAT reaction, forming NADH and the respective branched-
chain acyl CoA derivative of each BCAA. Maple Syrup Urine
Disease (MSUD) is an autosomal recessive disorder of this sec-
ond enzyme complex. In individuals with MSUD, the oxidation
of BCAAs is inhibited and, therefore, intake of BCAAs above the
daily requirement for protein synthesis causes accumulation of
BCAAs and their BCKAs to toxic levels (Chuang and Shih, 2001).
If left untreated, most patients experience seizures, changes in
muscle tone, and coma due to brain swelling. Analysis of MSUD
brains by magnetic resonance diffusion imaging spectroscopy
suggests impaired brain energy metabolism. Classically, there is
generalized edema in brain and spinal cord, with more intense
swelling in the cerebellar deep white matter, as well as edema in
other areas (Lewandowski and Johnston, 1990; Sener, 2002; Jan
et al., 2003; Righini et al., 2003; Ha et al., 2004; Parmar et al.,
2004). Neurological disorders frequently involve disruption of
the proper balance of these excitatory (glutamate) and inhibitory
(GABA) neurotransmitters, which result in altered excitability.
Recent studies have focused on the key role for BCAAs in
maintaining the synaptic pools of these neurotransmitters, while
examining the significance of BCAAs in post-traumatic patho-
physiology following traumatic brain injury. In mice there was
a significant reduction in the concentrations of BCAAs in the
hippocampus after a brain injury, coupled with a regionally spe-
cific alteration in both the concentration and cellular distribution
of BCKDC (Cole et al., 2010). Further, BCATc, but not BCATm
expression, was also diminished after a brain injury. These com-
bined changes were associated with significantly altered excitabil-
ity in the hippocampus and ultimately, impaired cognition.
Impressively, offering supplemental BCAAs in the drinking water
completely restored hippocampal BCAA concentrations to nor-
mal, and restored hippocampal excitability and cognitive perfor-
mance in brain-injured mice. Further, similar results have been
shown in clinical trials with humans, where there has been suc-
cess in treating severely brain injured patients by administering
IV boluses of BCAAs (Aquilani et al., 2005, 2008).
In this study immunohistochemical techniques were utilized
to determine the localization of BCKDC and BCATm in adult
rat brain. Understanding the distribution of these key enzymes
will have a major impact on the understanding, and possibly
treatment, of both traumatic brain injury and MSUD.
MATERIALS AND METHODS
ANIMALS AND TISSUES
BCATm
Because the BCATm antibody exhibits non-specific staining with
paraformaldehyde-fixed tissue, three adult male Sprague–Dawley
rats (250–300 g) were deeply anesthetized with sodium pentobar-
bital (30mg/kg) or ketamine/xylazine (90 and 10mg/kg, respec-
tively) then sacrificed. Freshly dissected brains were divided into
three equal-sized blocks along the rostral-caudal axis, and cryo-
embedded without fixation. Serial coronal sections (15μM thick-
ness) were collected on glass slides. Prior to immunolabeling,
the sections were immersed in acetone (20min) and lyophilized
overnight. Cresyl violet (Nissl) staining of selected sections pro-
vided anatomical reference points, identified with the aid of a rat
brain atlas (Paxinos and Watson, 1998).
BCKDC and BCATc
For localization of BCKDC, three anesthetized rats were sequen-
tially perfused via the left ventricle with 150mL phosphate
buffered saline (PBS) and 300mL of 0.1M sodium phosphate
buffer (pH 7.4) containing 4% paraformaldehyde. Brains were
removed and placed in the paraformaldehyde fixative for 24 h.
For frozen sections, the tissues were cryoprotected by sequential
immersion (24 h each) in 10, 20, and 30% sucrose/PBS solu-
tions, embedded in OCT compound (Sakura Finetek, Torrance,
CA) and frozen on dry ice. Some fixed brains were not frozen,
but were sectioned with a vibratome. Serial coronal sections
(34μM thickness) were obtained from six brains and stored as
floating sections in PBS at 4◦C or in antifreeze media (25%
glycerol, 25% ethylene glycol in 50mM phosphate buffer, pH
7.4) at −20◦C. Experimental procedures involving animals con-
formed to NIH guidelines and were approved by the Institutional
Animal Care and Use Committee of the Wake Forest University
Health Sciences.
ANTIBODIES
Polyclonal antibodies were raised in rabbits against either purified
recombinant human BCATm or BCATc, as previously described
and characterized in brain (Lieth et al., 2001). For BCATm
and BCATc, purified recombinant human BCATm and purified
N-terminal rat BCATc were used as antigens to raise antisera
in rabbits. The BCATc peptide contained the first 62 residues
in the BCATc sequence. For BCKDC, antibodies were raised in
rabbits immunized with a keyhole limpet hemocyanin-conjugate
of a peptide consisting of amino acids 32–50 of the E1α sub-
unit of the enzyme complex. Anti-E1α-peptide 32–50 recognizes
a band of∼45 kDa on immunoblots of protein from whole brain,
and recognizes a band of similar mass on immunoblots of pro-
tein from purified rat liver mitochondria (data not shown). All
antibodies were affinity-purified from IgG fractions of serum
by passage over columns of sepharose-conjugated immunogen
(purified BCATm, BCATc, or E1α-peptide), followed by elution
with low pH buffer and dialysis against 50% glycerol/water (Lieth
et al., 2001).
In order to determine the types of cells in which BCKDC-E1α
is expressed in the brain, colocalization with antibodies directed
against proteins characteristically expressed by various classes
of cells was performed. These marker proteins included: glial
fibrillary acidic protein (GFAP, an astrocyte marker, mouse mon-
oclonal 610566 from Becton Dickinson, Franklin Lakes NJ, used
at 2.5μg/ml), S100 (an intermediate filament protein, expressed
by astrocytes, mouse monoclonal S2532 from Sigma, used
at 6.4μg protein/ml); glutamic acid dehydrogenase (GAD67,
marker for GABAergic neurons, mouse monoclonal MAB 5406
from Chemicon/Millipore, Temecula CA, used at 10μg/ml),
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myelin basic protein (MBP, a marker for oligodendrocytes
and white matter, goat polyclonal sc-13194 from Santa Cruz
Biotechnology, Santa Cruz CA, used at 0.1μg/ml). Appropriate
secondary antibodies, conjugated to horseradish peroxidase or
to fluorophores (rhodamine, FITC, or Cy3), were obtained from
Jackson Immunoresearch Laboratories, West Grove PA, and used
at 1–3μg/ml. All products were “Multilabel”-antibodies that had
been affinity-purified and immunoadsorbed to remove cross-
reactive immunoglobulins.
IMMUNOHISTOCHEMISTRY
For localization of BCATm, slide-mounted brain sections were
rinsed with PBS, and then incubated for 60min in PBS contain-
ing 5% goat serum and 0.5% Triton X-100 to block nonspecific
IgG binding sites. The BCATm antibody (1:50) was applied for
2 h in a humidified chamber at 37◦C. Sections were rinsed with
PBS and then incubated for 60min with goat anti-rabbit IgG
conjugated to horseradish peroxidase. After rinsing with PBS,
color was developed with diaminobenzidine HCl/H2O2 (maxi-
mum exposure-10min). For the immunofluorescence study, goat
serum was used as the blocking agent, and anti-BCATm and
anti-GFAP as primary antibodies were used. These were followed
by donkey anti-rabbit IgG-rhodamine and donkey anti-mouse
IgG-FITC.
For localization of BCKDC-E1α, floating sections were rinsed
and blocked as described above, using 5% donkey serum. Sections
were incubated with rabbit anti-E1α-peptide (1:1000) either
alone or with one of themouse or goat antibodies directed against
the marker proteins listed above. Incubations were carried out
overnight at 4◦C, followed by 1 h at 25◦C. Sections were rinsed
three times for 10min each in PBS, and then incubated for 1 h
with appropriate fluorophore-conjugated secondary antibodies.
After PBS rinses, the sections were mounted on slides, and cover
slips were applied using Vectashield hard-set mounting medium
(Vector Laboratories Inc, Burlingame CA).
For localization of BCATc, floating sections were rinsed and
blocked as described above, using 5% donkey serum. Sections
were incubated with rabbit anti-BCATc (1:200). Incubations were
carried out for 1 h at 25◦C, then overnight at 4◦C, followed by
1 h at 25◦C. Sections were rinsed three times for 10min each in
PBS, and then incubated for 1 h with appropriate fluorophore-
conjugated secondary antibodies. After PBS rinses, the sections
were mounted on slides, and cover slips were applied using
Vectashield hard-set mounting medium (Vector Laboratories Inc,
Burlingame CA).
Peroxidase-labeled sections were viewed with a Zeiss Axioplan
2 microscope and images obtained via an AxioCam digital
camera and AxioVision imaging software (Carl Zeiss USA,
Thornwood, NY). Immunofluorescent images were acquired with
a Zeiss laser scanning confocal microscope (LSM 510) with asso-
ciated software. Images were converted and assembled using
Adobe Photoshop 6.0 or CS2 (Adobe Systems Incorporated, San
Jose CA).
WESTERN BLOTS
Western blots were performed using standard laboratory tech-
niques. Briefly, tissue samples were stored at −20◦C in 2×
Laemmli buffer with each vial prepared to contain an equal
concentration of protein (2mg/ml). After thawing and boiling
the samples for 4min, 20–40μg of protein were loaded per lane
on 4–12% Tris-glycine gradient gels (Invitrogen, Carlsbad, CA)
and subsequently transferred to PVDF membranes (Invitrogen,
Carlsbad, CA) at 24V for 2 h at 4◦C. After transfer, the mem-
brane was incubated for 1 h at room temperature with PBS-Tween
(PBS-T) containing 2.5% non-fat dairy milk. The membrane was
then incubated overnight with BCKD antibody. Following this,
the membrane was washed three times (5min each) with PBS-T,
and then incubated with anti-rabbit secondary antibodies (Cell
Signaling, Danvers, MA) for 1 h. Enhanced chemiluminescence
detection (Millipore, Billerica, MA) was used to detect the bands.
The films were then scanned into a computer for generation of
the Figure 1, which demonstrates the specificity of the antibody.
RESULTS
BCATm IN THE CEREBELLUM AND HIPPOCAMPAL FORMATION
In the cerebellum, immunolabeling for BCATm was most promi-
nent in astrocytes of the white matter tracts and in the distal
processes of the Bergmann glia of the cerbellar cortex (Figure 2).
There was some labeling of astrocytes of the granule cell layer.
Astrocytes in the deep cerebellar nuclei were also labeled for
BCATm (data not shown). Purkinje cells and granule cells were
not labeled. Co-localization of BCATm andGFAP (Figures 2C–E)
in astrocytes of the cerebellar white matter confirmed the astro-
cytic expression of BCATm.
In the hippocampal formation, immunoreactivity for BCATm
was restricted to astrocytes. Labeling for BCATm was seen in
astrocytes in the molecular, granule cell, and polymorphic lay-
ers of the dentate gyrus (Figures 3A,B). Labeled astrocytes in
the polymorphic layer typically had a stellate morphology, while
FIGURE 1 | Western blot analysis demonstrates the specificity of the
BCKD antibody. Using a molecular weight marker in lane A, a single band
was observed in lane B indicating that the antibody generated to identify
BCKD does recognize a band of the appropriate size and is specific to this
protein and does not recognize other antigens.
Frontiers in Neuroanatomy www.frontiersin.org May 2012 | Volume 6 | Article 18 | 3
Cole et al. Expression of BCATm and BCKD in the rat brain
FIGURE 2 | Immunolocalization of BCATm in the cerebellar cortex.
(A) Peroxidase immunolabel for BCATm. Label is detected in the molecular
(Mol) and granular layers (GL), but not in the Purkinje cell layer (PC).
Dotted line indicates the pial surface. (B) Higher resolution image of a
portion of the cerebellar white matter, showing label in cells that appear to
be astrocytes. (C) Rhodamine-immunolabel of BCATm in the cerebellar
white matter. (D) FITC-immunolabel of GFAP in the same section as
in panel C. (E) Merged image of panels C and D, demonstrating
label of BCATm in several astrocytes. Scale bars: (A) 100μm,
(B–E) 25μm.
FIGURE 3 | Immunolocalization of BCATm in the hippocampal
formation. (A) Nissl-stained coronal section showing portions of the
dentate gyrus (DG) and field CA1. Regions similar to those enclosed by
boxes B and C are shown at higher resolution in panels B and C.
(B) Peroxidase-visualized immunolabel of BCATm in the dentate gyrus.
Approximate boundaries of the granule cell layer (GCL) are shown by the
dotted lines. (C) Higher resolution image of BCATm-immunolabeled
astrocytes of the molecular layer (MOL) of the dentate gyrus.
(D) Rhodamine-immunofluorescent labeling for BCATm in the molecular layer
of the dentate gyrus. (E) FITC-immunofluorescent labeling for GFAP in the
same section as shown in panel D, showing GFAP in the proximal processes
and cell bodies of two astrocytes. (F) Merged image of panels D and E
demonstrating co-localization of BCATm and GFAP. Scale bars: (A) 200μm;
(B) 25μm; (C) 10μm; (D–F) 20μm.
those in the molecular layer usually had fewer andmore elongated
processes, the longest of which were generally oriented perpen-
dicular to the granular layer (Figure 3C). In the granule cell layer,
the most obvious labeling was of long processes of astrocytes at
the inner margin (Figure 3B). Labeling of the smaller, stellate
astrocytes extended throughout the stratum radiatum of the CA1
and CA2 hippocampal fields and into the fimbria of the hip-
pocampus (data not shown). BCATm-labeled astrocytic processes
often surrounded blood vessels, were concentrated along the hip-
pocampal fissure and in the subpial region, and extended to the
pial surface (data not shown).
Double immunolabeling of the hippocampal region for
BCATm and GFAP, an astrocyte specific protein, confirmed the
astrocyte specificity of BCATm expression. Figures 3D,E show
prominent immunoreactivity of BCATm and GFAP in cells of the
polymorphic layer.Merging the two images (Figure 3F) shows the
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FIGURE 4 | Immunolocalization of BCATm in the spinal cord.
(A) Anti-BCATm strongly labels elongate, radially oriented elements in
the white matter of the spinal cord. (B) Labeling for GFAP in the same
section as shown in panel A shows that the radial elements are glial
processes. (C) The merged image of panels A and B shows nearly
complete colocalization of BCATm with GFAP. (D) (Inset) Cell bodies
of glial cells are labeled only for BCATm. Scale bar: (A–C) 100μm.
(D) 20μm.
virtually complete co-localization of GFAP and BCATm, confirm-
ing that BCATm is expressed strictly in astroglia.
BCATm IN THE SPINAL CORD
There was striking labeling for BCATm (Figure 4A) in radially
oriented structures in the spinal cord white matter. The labeling
pattern was coincident with that for GFAP (Figure 4B), indicating
that the astrocytic processes were BCATm-positive (Figure 4C).
Many, but not all, BCATm-labeled cell bodies in the white matter
were clearly associated with GFAP-labeled processes (Figure 4D).
However, this could be attributed to the intracellular distribution
of BCATm and GFAP, with BCATm localizing in mitochondria in
the cell bodies, while GFAP strongly labels astrocytic processes.
BCKDC-E1α IN THE CEREBELLUM
Examination of the labeling for BCKDC-E1α in the cerebellar cor-
tex revealed intense labeling of structures lying in the Purkinje
cell layer, as well as light labeling of Purkinje cell bodies and
some neurons of the molecular layer (Figure 5). The processes
of astrocytes and Bergmann glia were not labeled for BCKDC-
E1α. Close examination of the labeling pattern for BCKDC-E1α
in the Purkinje cell layer revealed that the heavily labeled struc-
tures lie at the periphery of the Purkinje cells. The structures are
clearly not labeled for GFAP, a marker for filamentous protein of
astrocytes/Bergmann glia. In sections that were double immuno-
labeled for BCKDC-E1α and the GABAergic marker enzyme
GAD67, Purkinje cell cytoplasm was clearly labeled for GAD, but
the GAD label did not overlap with that of BCKDC-E1α (Figure 5
inset).
BCKDC-E1α immunoreactivity was also present in neurons of
the deep cerebellar nuclei, where it contrasted sharply with the
lack of label in the white matter (Figure 6). There was a simi-
lar paucity of label for BCKDC-E1α in the white matter of the
cerebellar cortex (data not shown). This indicates that oligoden-
drocytes and white matter astrocytes in the cerebellum do not
express BCKDC-E1α.
BCKDC-E1α IN THE HIPPOCAMPAL FORMATION
In the hippocampal formation, BCKDC-E1α immunoreactivity
was generally of low-intensity, as shown in Figure 6. Labeling for
BCKDC was restricted to cell bodies, most clearly to those of
the granule cell layer of the dentate gyrus. Labeling for BCKDC-
E1α in neurons in the hippocampus took the form of a ring of
immunoreactivity surrounding an unlabeled nucleus (Figure 7A)
and did not extend into the neuronal processes. In addition, co-
labeling for GFAP showed that astrocytes in the hippocampus are
not labeled for BCKDC-E1α (Figures 7B,C). In Figure 7, the pat-
tern of expression of BCKDC-E1α can be contrasted with that for
BCATc, which is shown for a similar section through the den-
tate gyrus (Figure 7D). BCATc is the neuronal isoform of the first
enzyme in the BCAA catabolic pathway (Hall et al., 1993). BCATc
is cytosolic, and is present mostly in the processes of neurons in
the hippocampus and neocortex, as well as in the cerebellum (see
Discussion).
BCKDC-E1α IN THE CEREBRAL CORTEX
In the cerebral cortex, the intensity of BCKDC-E1α is in clearly
labeled neuronal bodies (Figure 8). In the pyramidal layers, large
cell bodies are more typically immunoreactive for BCKDC-E1α,
while some processes occasionally expressed BCKDC-E1α, as
well. GFAP most strongly labeled astrocytes near the apical sur-
faces of the cortex. These labeling patterns are consistent with that
observed in other regions of the brain.
BCKDC-E1α IN THE HYPOTHALAMUS AND OTHER BRAIN REGIONS
Immunoreactivity for BCKDC in the hypothalamus continued
the pattern of low-intensity labeling of neuronal cell bodies
seen in other brain regions. The salient features are illustrated
by Figure 9, in which neuronal cell bodies in the arcuate
nucleus are consistently labeled. Small S100-positive cells astro-
cytes (Figure 9B) appear to be labeling astrocytes and tany-
cytes along the ventricle surface. The subependymal region, like
the subpial regions elsewhere, is characterized by S100-positive
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FIGURE 5 | Immunolocalization of BCKDC-E1α in the cerebellar cortex.
Co-localization of BCKDC-E1α (red) and GFAP (green) in the cerebellar
cortex. Labeling for BCKDC is very prominent in structures located along
the plane of Purkinje cell bodies (PC, cells marked by ∗; BCKDC label
indicated by arrows). Label for BCKDC is also seen in some cells of the
molecular layer (Mol). Immunolabel for GFAP is associated with the distal
process of the Bergmann glial cells (BG, arrows) and with astrocytes in the
granule cell layer (GC). (Inset) Merged image of co-labeling for BCKDC (red)
and glutamate dehyrogenase (GAD), a marker for GABAergic cells. Purkinje
cell bodies are clearly demarcated by anti-GAD. Strongest labeling for
BCKDC is either at the far periphery of the Purkinje cells, in a distinct
structure associated with surfaces of Purkinje cell bodies. Scale bars:
(A) 50μm. (B–E) 25μm.
processes, with few BCKDC-E1α-positive cell bodies. At the ven-
tricular interface, the ependymal cells show strong labeling for
BCKDC-E1α at their ciliary surfaces. This is especially evident in
Figure 9C. At higher resolution, labeling of neurons in the arcuate
nucleus for BCKDC-E1α can be compared with the distribu-
tion of glial elements (astrocytes and/or tanycytes) that form the
blood-brain barrier in the median eminence and are immunore-
active for S100 (Figures 9D–F). The glial cells are not labeled for
BCKDC-E1α. Elsewhere in the brain (e.g., in the thalamus and
brain stem), labeling for BCKDC-E1α is similar to that shown
in Figure 9 for the hypothalamus—neuronal cell bodies are gen-
erally immunoreactive (data not shown). In addition, glial cells
were not labeled for BCKDC-E1α. As shown for the cerebellum
(Figure 5), there was no overlap of BCKDC-E1α immunoreactiv-
ity with MBP-labeling of white matter tracts.
FIGURE 6 | Immunolocalization of BCKDC in deep cerebellar nuclei and
white matter. (A) Labeling for BCKDC is strong in the cell bodies of
neurons of the deep cerebellar nuclei. Dashed white line marks the border
between the nucleus and an unlabeled white matter tract.
(B) Immunolabeling for myelin basic protein (MBP), a marker for myelin and
oligodendrocytes, in the same section as in panel A. (C) Merged image of
panels A and B. There is virtually no co-labeling of cells for BCKDC and
MBP. (D) Co-label of the Purkinje cell layer for BCKDC and MBP. Structures
labeled for BCKDC are not labeled for MBP, indicating that they are not
oligodendrocytes. (E) Control section showing the Purkinje cell layer of a
section incubated with secondary antibodies only. The image was obtained
using the same microscope settings, and processed in the same way as
the image in panel A. Scale bars: (A–C) 100μm. (D,E) 50μm.
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FIGURE 7 | Immunolocalization of BCKDC in dentate gyrus. (A) BCKDC
immunolabel is present in neurons of the granule cell layer (GCL). Arrows
indicate specific labeling of large neurons of the polymorphic layer (PoM).
(B) Immunolabel for the astrocyte marker GFAP in the same section as in
panel A. Astrocyte processes are labeled in the granule cell polymorphic
layers. Astrocyte cell bodies are also labeled in the polymorphic layer.
(C) Merged image of panels A and B. There is no co-labeling of cells for
BCKDC and GFAP. (D) Labeling of the dentate gyrus for BCATc, one of the
enzymes that generates branched-chain α-keto-acids that are the substrates
for BCKDC. As shown previously (Sweatt et al., 2004a), BCATc is present
only in cells at the inner margin of the granule cell layer. Scale bars:
(A–C) 25μm. (D) 20μm.
FIGURE 8 | Immunolocalization of BCKDC in the cerebral cortex.
BCKDC is clearly expressed in the perinuclear regions of neurons in the
pyramidal cell bodies. GFAP immunoreactivity is observed in astrocytic
processes primarily in the apical surface. Scale bars: 100μm.
BCKDC-E1α IN THE SPINAL CORD
Cell bodies in both the white matter and gray matter of the spinal
cord were labeled for BCKDC-E1α (Figure 10). In the white mat-
ter, neuronal cell bodies that were positive for BCKDC-E1α were
often in close proximity to S100-positive elements (astrocytes).
Since much of the S100 labeling was located on structures that
appeared to be blood vessels, the S100 was probably located in
perivascular astrocytes.
DISCUSSION
The key findings of this study are the apparent restriction of
BCATm expression to astrocytes, Bergmann glial cells and spinal
cord radial glia, while BCKDC-E1α is expressed by neurons and
ependymal cells. Most remarkable, in light of the white mat-
ter edema that occurs in MSUD, is that BCKDC-E1α, which is
defective in MSUD, is not present in white matter tracts.
BCATm
For BCATm, the astrocytes in which it is heavily expressed are
most often located in the neuropil and myelinated tracts, and not
in gray matter. Labeling for BCATm in these astrocytes extends
into the cell processes, indicating a wide intracellular distribu-
tion of the enzyme in this cell type. The intracellular pattern of
BCATm expression in astrocytes follows the pattern of labeling for
cytoskeletal elements (GFAP), though in spinal cord, cell bodies
are also clearly labeled. This pattern may have resulted from the
need to use fresh-frozen tissue to demonstrate BCATm in brain
tissues. Chemical fixation would be expected to preserve mito-
chondria, which would exhibit a punctate labeling pattern for
BCATm.
These results support the hypothesis that BCATm contributes
nitrogen to the glutamate-glutamine cycle via the astrocyte.
Uptake of BCAAs into the brain provides an important source
of nitrogen, with BCATc and BCATm mediating the transfer
of α-amino nitrogen from BCAA to glutamate which can then
donate nitrogen to other brain amino acids. Net nitrogen trans-
fer from BCAAs occurs when the BCAA carbon skeleton is lost
due to oxidation (Hutson et al., 2005). Further, the rate of BCAA
oxidation is greater than the rate of incorporation of BCAA
into protein (Cooper and Plum, 1987). Although the distribu-
tion of these enzymes in humans has not been reported, human
brain contains 20% of total body capacity to oxidize BCAAs
(Suryawan et al., 1998). Current paradigms suggest that fol-
lowing the vesicular release of the neurotransmitter glutamate,
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FIGURE 9 | Immunolocalization of BCKDC in the hypothalamus.
(A) Labeling for BCKDC is present in cells of hypothalamic nuclei,
as well as in ependymal cells lining the third ventricle (III). (B) Immunolabel
for S100 in the same section as in panel A. (C) Merged image of panels
A and B. BCKDC-positive cells are not co-labeled for S100. Labeling for
BCKDC in the ependymal cells clearly lies above a layer of cells that
express S100. (D) Higher resolution image of the arcuate nucleus (Arc),
near the transition to the median eminence (ME). (E) Immunolabel
for S100 in the same section as in panel D. (F) Merged image of panels
D and E. Neurons of the arcuate nucleus are labeled for BCKDC,
with no overlap of labeling for S100. S100 labeling appears in occasional
cells of the nucleus, as well as in processes of cells lying in the
transition zone to the median eminence. Scale bars: (A–C) 100μm.
(D–F) 50μm.
astrocytes take up a significant portion of the glutamate to pre-
vent excitotoxicity. The astrocyte enzyme, glutamine synthetase,
converts glutamate to glutamine using free ammonia. The glu-
tamine is then shuttled back to the neuron where it can be
re-converted to glutamate and either re-used as a neurotrans-
mitter or oxidized (Berl and Clarke, 1983). This system is not
100% efficient because glutamate is oxidized to pyruvate, there-
fore, a combination of de novo synthesis and vascular delivery of
and/or glutamine is required to maintain glutamate homeosta-
sis (Gamberino et al., 1997; LaNoue et al., 2007). A key finding
of this study, that BCATm is astrocyte specific, reveals that this
BCAT isoform is in a key position to remove α-ketoglutarate
from the TCA cycle to form glutamate. Furthermore, the localiza-
tion of BCKDC suggests that BCKAs produced from the BCATm
reaction are oxidized outside astrocytes, which is consistent with
the BCAA cycle hypothesis (Yudkoff et al., 1996b; Hutson et al.,
1998).
Studies of astrocyte cultures reveal a high capacity for leucine
uptake, with BCAAs being accumulated against a concentration
gradient. Transfer of BCAA nitrogen into glutamate and then into
glutamine occurs in primary cultures of rat astroglia (Yudkoff
et al., 1983, 1994, 1996b; Hutson et al., 1998; McKenna et al.,
1998). Studies of cultured neonatal cortical astrocytes support the
role of BCAAs in de novo glutamate synthesis (Gamberino et al.,
1997; Waagepetersen et al., 2001).
BCKDC E1α
Labeling of BCKDC E1α in neurons has a pattern consistent with
mitochondrial localization, i.e., punctate labeling of the perinu-
clear cytoplasm. Interesting exceptions are the preferential label-
ing of neuronal processes in the cerebral cortex and the labeling of
radially oriented glial processes in the spinal cord. The punctuate
pattern of labeling in the cerebral cortical neurons suggests local-
ization of the enzyme in mitochondria in large dendrites. In the
cerebellum, the strong labeling for BCKDC-E1α in the Purkinje
cell layer could represent a mitochondria-rich region either in the
proximal portion of one of the large dendrites of the Purkinje
cells or in structures associated with the Purkinje cell surface.
These could include elements of other neurons and/or glial cells,
such as Bergmann glia, which lie close to the labeled structure.
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FIGURE 10 | Immunolocalization of BCKDC in the spinal cord.
(A) Labeling for BCKDC in the white matter is found on cell bodies
and fine, radially oriented processes. (B) Labeling for an astrocyte marker,
S100, is present over some cell bodies, but is mostly associated with
serpentine structures that resemble blood vessels. (C) The merged
image of panels A and B shows that BCKDC-positive cell bodies
are often associated with S100-positive processes. Scale bars:
(A–C) 50μm.
Labeling for BCKDC-E1α is present in a variety of neuronal types:
glutamatergic (e.g., hippocampal granule cells), GABAergic (e.g.,
Purkinje cells), and cholinergic (motor neurons). In addition,
labeling of neurons in the arcuate nucleus indicates expression
of BCKDC-E1α in neurons that produce neuropeptides that are
involved in food intake regulation. Injection of leucine into the
third ventricle has been reported to result in inhibition of food
intake (Cota et al., 2006; Blouet et al., 2009).
The complete absence of BCKDC in astrocytes indicates BCAA
oxidation is neuronal and suggests that as in the periphery,
there is translocation of BCAA and BCKA between cells and
separation of transamination and oxidation except in neurons
that contain both BCATc and BCKDC. Depending on the spe-
cific neuron, the location of BCATc and BCKDC indicates that
either reamination/transamination or oxidative decarboxylation
of BCKAs occurs in neurons. The intracellular separation of
the two enzymes, BCATc appearing primarily in processes and
pre-synaptic varicosities while BCKDC occurs primarily in cell
bodies, suggests a potential spatially regulated mechanism for
determining the ultimate fate of BCKAs.
Disruptions in BCKDC result in accumulation of both BCKAs
and BCAAs in neurons and astrocytes. The disease is lethal if
untreated and the block at BCKDC results in accumulation of
both BCAAs and BCKAs to neurologically toxic levels (Jan et al.,
2003). This is accompanied by systemic metabolic decompen-
sation. Magnetic resonance imaging, computerized tomography
scans and autopsies have all demonstrated generalized brain
edema, with more intense swelling in the cerebellar deep white
matter with severe status spongiosus, as well as edema in the
posterior brainstem, the posterior limbs of the internal capsule
and the posterior aspect of the centrum semiovale (Riviello et al.,
1991; Sener, 2002; Righini et al., 2003; Ha et al., 2004; Parmar
et al., 2004). The affected brain regions are most notably the
white matter tracts, which show almost no labeling for BCKDC.
Flooding the brain with BCAAs and BCKAs may have direct
effects on the white matter, especially since white matter lacks the
BCKDC that might detoxify by catabolizing BCKAs. Reamination
of the BCKAs by the neuronal BCATc isozyme could deplete
neuronal glutamate and upset the balance of excitotoxic and
inhibitory neurotransmission in areas where BCATc is expressed.
The α-keto acid of leucine, KIC, is thought to be the toxic metabo-
lite (Chuang and Shih, 2001), which is supported by the lack of
MSUD symptoms found in the BCATm knockout mouse (She
et al., 2007). Alternatively, the high levels of BCAAs and BCKAs
in MSUD may have indirect effects on pathways that regulate the
balance of fluid, ions, and small molecules in myelinated tracts.
The implications of these findings for disorders of the BCAA
metabolizing system are several. First, it appears that coordi-
nated action of BCATc, BCATm, and most importantly, BCKDC
in maintaining BCAA/BCKA homeostasis occurs in cell layers
and neuropil, and not in the white matter tracts that undergo
edema in MSUD. The only enzyme of the system that is present
in white matter is BCATc, which is found in tract axons (Garcia-
Espinosa et al., 2007). In MSUD, the deficit in BCKDC activity
would bemost severe in (or even restricted to) graymatter, among
neurons and astroglia or their derivatives. Effects on white mat-
ter could result from direct action of BCAA/BCKAs on tract
components or from indirect effects of the BCAA/BCKA on path-
ways originating in the cell body and that control white matter
homeostasis. That the white matter edema of MSUD is reversible
(Jan et al., 2003) might indicate a direct effect. In particular,
since BCATc is distributed evenly in axons in white matter, it is
tempting to speculate that this enzyme has a regulatory function
(metabolic/structural) that may involve binding and or cataly-
sis of BCAA/BCKA, and that BCATc normally operates without
need of local BCKDC-E1α activity. This role may be disrupted in
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MSUDwhen the BCATc enzyme is overwhelmed by globally high
levels of BCAA/BCKA.
BCAAs may also be important to the injured brain where
decreased expression of BCATc and BCKD has been observed,
while BCATm was not affected. Disruption of these enzymes
could have a profound impact on the glutamate/glutamine cycle,
which may account for some of the pathophysiology follow-
ing traumatic brain injury. One putative mechanism of injury
is known as “glutamate excitotoxicity” in which dysregulated
release of glutamate from pre-synaptic excitatory neurons floods
the synaptic cleft. The astrocyte then clears the excess glutamate.
Normally, some of this glutamate would be recycled, however, the
decreased expression of BCATc and BCKD suggests that this may
not be occurring properly. Indeed, this may result in depleted
neurotransmitter pools accounting for regionally specific hypoex-
citability after a brain injury.
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